Another inhibitor CPI-1205, disturbing the interaction of EZH2 with PRC2 complex, is currently evaluated in a phase 1 clinical trial in patients with B-cell lymphomas (NCT02395601) [97]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.